Pharmafile Logo

6 trends shaping the future of personalized medicine

Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators.

With precision medicines accounting for at least 25% of FDA approvals in the last 7 years, personalized healthcare is far from niche. Personalization is one of the foundations of modern healthcare, advancing how we realize better outcomes for patients and society.

Related forces like value-based care and patient empowerment are bolstering the movement towards personalization. At the same time, the COVID-19 pandemic has disrupted the health landscape—illuminating inequities, spurring technological innovation, and further elevating the role of human behavior in health.

Bringing together a wide array of stakeholders—from the pharmaceutical and diagnostic industry to providers, payers, patients, and clinicians—is crucial for exchanging perspectives and ideas in this changing landscape. This is just what the Personalized Medicine Coalition did at its 16th annual conference, “From an Enterprise to an Era,” in May.

Read on for our key takeaways from the rich conversations at the conference and learn what they mean for innovators working to continue advancing personalized healthcare.

DOWNLOAD THE FULL ARTICLE HERE

This content was provided by Avalere Health

Company Details

 Latest Content from  Avalere Health 

5 ways we’re enhancing our services to support our clients in 2023

Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.

Why it’s time to apply a payer lens to your early pipeline planning

Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial...

The fast-paced future of cell and gene therapies

In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist...

Omnichannel scientific engagement and the use of archetypes to drive personalization

Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can...

The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia

With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20...

Report: Reinventing product and portfolio value for the biopharmaceutical industry

Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...

Practical advice for Early Scientific Advice (ESA) in HTA submissions

A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...

Geoff Thorne joins FH as Chief Technology Officer to drive innovation for clients

The experienced executive will expand our cross-functional omnichannel, data and analytics, and technology offerings, developing effective solutions to meet our clients’ evolving needs.

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas

Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments.

How the WHO hepatitis strategy measures up in the field

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...